FibroGen (NASDAQ:FGEN) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of FibroGen (NASDAQ:FGEN) in a research report sent to investors on Sunday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

Separately, William Blair reaffirmed a market perform rating on shares of FibroGen in a research note on Monday, June 3rd.

FibroGen Stock Up 9.9 %

FGEN opened at $0.42 on Friday. The company has a market cap of $41.28 million, a PE ratio of -0.17 and a beta of 0.71. FibroGen has a twelve month low of $0.33 and a twelve month high of $2.93. The company has a 50-day moving average price of $0.85 and a 200 day moving average price of $1.36.

FibroGen (NASDAQ:FGEN) last announced its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.09. The firm had revenue of $50.64 million for the quarter, compared to analyst estimates of $33.00 million. During the same period in the previous year, the company earned ($0.65) EPS. As a group, sell-side analysts expect that FibroGen will post -1.05 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Deyaa Adib purchased 22,123 shares of the business’s stock in a transaction that occurred on Wednesday, June 12th. The stock was purchased at an average price of $1.17 per share, with a total value of $25,883.91. Following the completion of the acquisition, the insider now owns 82,123 shares in the company, valued at $96,083.91. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 1.98% of the company’s stock.

Hedge Funds Weigh In On FibroGen

A number of institutional investors have recently bought and sold shares of FGEN. Alpine Global Management LLC acquired a new stake in shares of FibroGen during the 1st quarter worth approximately $25,000. Delap Wealth Advisory LLC purchased a new position in FibroGen in the first quarter worth approximately $27,000. Accel Wealth Management acquired a new stake in FibroGen during the first quarter worth $103,000. Point72 DIFC Ltd raised its position in FibroGen by 734.2% in the second quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 45,990 shares during the period. Finally, Doheny Asset Management CA acquired a new position in shares of FibroGen in the 2nd quarter valued at $48,000. 72.71% of the stock is owned by hedge funds and other institutional investors.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.